INTRODUCTION
Hemolytic transfusion reactions (HTRs) are dangerous complications of blood transfusion. IgMmediated HTRs (IgM-HTRs) occur acutely, are usually due to ABO incompatibility, typically cause intravascular hemolysis, and can lead to shock, renal failure, coagulopathy, and death 1 .
Although infrequent, IgM-HTRs have a high mortality rate. IgG-mediated HTRs (IgG-HTRs), are more common, but usually less severe, than IgM-HTRs; they can occur acutely or be delayed, typically cause extravascular hemolysis, and occasionally result in renal failure, coagulopathy, and death 2 . Symptomatic immune-mediated red blood cell (RBC) destruction also occurs in autoimmune hemolytic anemia (AIHA) 3 , blood-group incompatible transplantation 4 , and immune thrombocytopenic purpura treated with Rh-immune globulin 5 . Although various different modalities are used to treat HTRs, there is no definitive evidence regarding efficacy.
Given the sporadic nature of HTRs, designing human trials to evaluate treatment options is difficult. Therefore, to study the mechanisms underlying HTRs, to evaluate the efficacy of existing treatments, and to develop new treatments, a relevant, inexpensive, and tractable animal model is required 6 . A mouse model would be ideal for this purpose 7 , given the abundance of reagents and relevant knockout (KO) and transgenic (Tg) animals. Although mouse blood group polymorphisms exist 8 , and transfused incompatible mouse RBC (mRBC) are rapidly cleared 9, 10 , no one has exploited these findings to develop a model of HTRs. The availability of a Tg mouse expressing human glycophorin A (hGPA) on mRBC 11 offers an approach using a well-described glycoprotein target and well-characterized reagents.
We describe initial studies validating mouse models of IgG-and IgM-mediated alloimmune hemolysis. Thus, mRBC from hGPA-Tg donors were transfused into non-Tg recipients that were passively immunized with IgG or IgM hGPA-specific monoclonal antibodies (MAb). The clearance of the transfused mRBC was quantified and the roles of complement and Fcγ receptors were evaluated.
only.
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MATERIALS AND METHODS

Antibodies
Purified MAb NaM26-2H12 (IgG3), NaM26-3F4 (IgG1), and NaM10-6G4 (IgG2a), which recognize peptide epitopes on the M and N forms of hGPA 12 , were purchased from EFS (Nantes, France). Hybridomas producing MAb 6A7, an IgG1 specific for a sialic acid-dependent epitope on M-type hGPA [13] [14] [15] , 10F7, an IgG1 recognizing a non-polymorphic epitope on hGPA 13, 14 , and
J11d, a rat IgM recognizing CD24 on mRBC 16, 17 , were purchased from the ATCC (Manassas, VA). The hybridoma producing MAb N92, an IgG2a anti-N Mab 18 , was provided by Elwira Lisowska (Ludwik Hirszfeld Institute, Wroclaw, Poland). The hybridoma producing MAb E4, an
IgM that recognizes a non-polymorphic epitope present on hGPA 19 , was provided by Marilyn
Telen (Duke University, Durham, NC).
Throughout culture and MAb purification, endotoxin contamination was minimized. IgG
MAbs were purified by immunoaffinity chromatography. Thus, 5 ml of goat anti-mouse IgG agarose (Sigma, St. Louis, MO) in a disposable 10 ml chromatography column (Pierce, Rockford, IL) were equilibrated with 50 ml of column wash buffer (CWB; 50 mM Tris, pH 8.0, prepared using endotoxin-free water and 1.0 M Tris-HCl, pH 8.0 (Mediatech, Herndon, VA)). A peristaltic pump and pyrogen-free tubing (VWR, West Chester, PA) were used to perfuse the column with 100 ml of conditioned medium or ascites at 1 ml/min overnight at 4°C. The column was then washed with 50 ml of CWB and eluted with Immunopure IgG elution buffer (Pierce, Rockford, IL) in 4 ml fractions into tubes containing 1 ml of 1.0 M Tris-HCl in endotoxin-free water, pH. 8.0. Peak fractions (i.e. A 280nm > 0.050) were pooled, changed into endotoxin-free
Tris-buffered saline (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl (Teknova, Hollister, CA)), and concentrated to 1 mg/ml (determined by the BCA Assay (Pierce)) using Centriprep YM-10 centrifugal filters (Millipore, Billerica, MA). Similarly, the IgM J11d and E4 MAbs were purified using a protein L column (Pierce) and the mannose binding protein-based Immunopure
IgM Purification Kit (Pierce), respectively.
All MAbs used in vivo were purified to electrophoretic homogeneity. Endotoxin levels were quantified using the LAL QCL-1000 kit (Cambrex, East Rutherford, NJ). The purified
MAbs were clear solutions with no visible precipitates; however, they were not further evaluated to exclude the presence of higher oligomers or aggregates. To measure Mab activity, min at 4°C, SN absorbance at 414 nm was determined. Non-opsonized human RBC and mRBC were negative controls. As positive controls, RBC were completely hemolyzed using distilled water instead of GVB+2 buffer; after hemolysis, 10 µl of guinea pig serum were added.
Mice
Wild type C57BL/6 and BALB/C mice, and FcγRIIb knockout (KO) mice on the BALB/C background, were from Taconic Labs (Hudson, NY). FVB/NJ mice were purchased from Jackson Laboratories (Bar Harbor, ME). FcRγ KO 20 , complement C3 KO 21 , and FcγR/C3 double-KO mice (all on the C57BL/6 background) were maintained by Dr. Clynes; C3 KO breeding pairs were provided by Michael Carroll (Harvard University, Boston, MA). Animal protocols were approved by the Institutional Animal Care and Use Committee at the Columbia University. Narla Mohandas (New York Blood Center) provided breeding pairs of hGPA-Tg mice 11 , which were constructed on the FVB/NJ background using human BAC clone 159F4
(Catalog #982132; Invitrogen), which contains hGPA. FVB/NJ mice do not express functional complement C5 protein 22 .
A multiplex polymerase chain reaction (mPCR) assay identified hGPA-Tg mice, using genomic DNA extracted from tail biopsies to amplify a 291-bp hGPA sequence using forward 
Passive immunization
Prior to injection, MAbs were dialyzed against endotoxin-free NS (Phoenix Scientific, St.
Joseph, MO). Recipients received IgG MAbs by intraperitoneal injection 16h before transfusion;
alternatively, the IgM MAb was infused into the right jugular vein 2 min before transfusion.
Preparation of 51-Cr labeled mRBC
Donors were anesthetized, exsanguinated by cardiac puncture using 25-gauge needles and heparin-coated syringes, and euthanized. For each transfusion, a 1 ml aliquot of a 3% suspension of washed mRBC in a pyrogen-free 1.5 ml microfuge tube was centrifuged at 10,000 x g for 3s, SN was removed, and packed RBC (pRBC) were re-suspended in 100 µl of endotoxin-free NS and 20 µl of 51-Cr (1 mCi/ml; GE Healthcare, Piscataway, NJ). Following 30 min at RT, the tube was centrifuged, SN removed, and the pRBC re-suspended in 100 µl of NS.
Transfusion of 51-Cr labeled mRBC
The recipients were anesthetized and, using sterile technique, a 1 cm vertical midline incision was made and the left jugular vein exposed by blunt dissection. The 51-Cr labeled mRBC (~30 µl of pRBC) in a 25-gauge butterfly was transfused over 5s into the jugular vein. Following transfusion, hemostasis was achieved, and the wound was closed. This procedure was completed in less than 5 min. A zero timepoint (T=0) sample of ~25 µl of blood was then obtained from the retro-orbital plexus.
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Survival of transfused RBC
At designated times post-transfusion, mice were anesthetized and an endpoint sample of ~25 µl of retro-orbital plexus blood was obtained. Microhematocrit tubes containing the T=0 and terminal blood samples were centrifuged for 1 min; the height of the pRBC column was measured and the tubes analyzed for counts per minute (CPM) in a gamma counter (PerkinElmer, Wellesley, MA). The percentage of radiolabeled mRBC remaining at time "n" following transfusion (T=n) was calculated as:
{(CPM/mm of pRBC in the T=n sample)/(CPM/mm of pRBC in the T=0 sample)} x 100
Following the terminal time point sample, recipients were exsanguinated and euthanized.
Determination of hemoglobinuria
In some experiments, recipients were maintained in metabolic cages. Urine was collected from metabolic cages while mice were alive; bladder urine was also collected at autopsy. Urine absorbance was measured by wavelength scanning spectrophotometry at 300-700 nm using a spectrophotometer (Nanodrop Technologies, Wilmington, DE). 
RESULTS
Further characterization of hGPA-Tg mice
Animal husbandry
There were no behavioral differences between hGPA-Tg and wild type FVB/NJ mice. hGPA-Tg mice were healthy, bred well, bore litters of expected size (averaging ~8 neonates/litter), and nurtured their offspring attentively.
Serological characterization of hGPA-Tg-mRBC
In the initial study of hGPA-Tg mice, hGPA expression on mRBC was characterized using only two anti-hGPA MAbs, which had no blood group MN specificity 11 . We extended these studies using well-characterized anti-hGPA MAbs [12] [13] [14] [15] 18, 19 . Hemagglutination with anti-M and -N MAbs (6A7 and N92, respectively) revealed that hGPA-Tg-mRBC expressed the M allele (Table 1) .
These results are particularly interesting because 6A7 recognizes a sialic acid-dependent epitope 15 , and mouse and human RBC sialic acids differ 24 . In addition, the NaM16-1B10, NaM10-2H12, NaM26-3F4, and 10F7 MAbs, which recognize non-allelic hGPA peptide epitopes [12] [13] [14] , agglutinated human RBC and hGPA-Tg-mRBC, but not wild type mRBC (Table   1) . Similar results were obtained with the hGPA peptide-specific NaM10-6G4 and E4 MAbs (not shown). The variation in agglutination titer seen with 10F7 and NaM26-3F4 with different RBC isolates is intriguing, but is not yet understood. Taken together, these results demonstrate that a broad array of anti-hGPA MAbs recognize a glycosylated recombinant form of hGPA on hGPATg-mRBC.
Genotyping and phenotyping hGPA-Tg mice
We developed mPCR and hemagglutination assays to provide a definitive means of identifying hGPA-Tg mice. Thus, mPCR of genomic DNA yielded a 218 bp band when the hGPA Tg was present, and an 88 bp band corresponding to mouse glycophorin 23 , as an internal standard ( Figure   1 ). In contrast, mPCR results from mice lacking the hGPA Tg yielded only the 88 bp mouse glycophorin band ( Figure 1 ). For older mice, hemagglutination assays using the 6A7 anti-hGPA
MAb allowed phenotypic confirmation of the presence or absence of the Tg. Thus, MAb 6A7
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Identification of the hGPA Tg integration site
Initially, it was not clear whether the hGPA Tg integrated at one or multiple loci 11 . FISH provides a definitive means of examining chromosomal integration sites. As a positive control, hGPA is a single copy gene in human leukocytes and maps to chromosome 4q28-q31 ( Figure   2A ). Similarly, in hGPA-Tg mouse bone marrow cells, the hGPA Tg integrated at a single locus 
RBC survival studies
IgG-mediated hemolysis in vivo of transfused incompatible mRBC
When transfused into wild type FVB/NJ and C57BL/6 mice that had been passively immunized with varying amounts of the 10F7, NaM10-2H12, and NaM10-6G4 IgG MAbs, incompatible hGPA-Tg-mRBC were promptly cleared from the circulation in amounts proportional to the amount of infused anti-hGPA MAb. For example, when immunized with increasing amounts of MAb 10F7, 24-hour RBC survival progressively decreased ( Figure 3 ). Because of these results, 500 µg of MAb 10F7 were used subsequently. Similar dose-response experiments with NaM10-2H12 and NaM10-6G4 (not shown), revealed that 50 µg of each of these MAbs would suffice for inducing dramatic RBC clearance ( Table 2) . As negative controls, no destruction of transfused, compatible, wild type mRBC was observed in mice immunized with any IgG anti-hGPA MAbs (not shown). In addition, when an isotype-matched irrelevant IgG1 MAb was used as a control for 10F7, the survival of hGPA-Tg-mRBC was normal at 24 hr (D.A.S, S.L.S., and James C.
Zimring, unpublished data). Similarly, no destruction of transfused hGPA-Tg-mRBC was detected in unimmunized recipients (not shown and see Table 3 , below). Therefore, despite the H-2 difference between donors (FVB/NJ background) and recipients (i.e. C57BL/6 and BALB/C), no "naturally-occurring" anti-H-2 antibodies caused accelerated mRBC destruction 8, 10 . (Table 3B) .
Thus, although complement participates in IgG1-mediated clearance of hGPA-Tg-mRBC, activating Fcγ receptors play a dominant role. In contrast, when immunized with the IgG3 NaM10-2H12 anti-hGPA MAb, hGPA-Tg-mRBC destruction was markedly inhibited in C3 KO mice and only moderately inhibited in FcRγ KO mice (Table 3A) ; thus, complement is dominant, with some contribution by activating Fcγ receptors. With both of these Mabs, clearance of hGPA-Tg-mRBC was markedly, but not completely, inhibited in FcγR/C3 double-KO mice, suggesting that other mechanisms may also be involved in mRBC clearance.
Inhibitory Fcγ receptors were also investigated using FcγRIIb KO mice (BALB/C background). No difference in IgG3-mediated clearance of incompatible mRBC by Mab NaM10-2H12 was observed when comparing FcγRIIb KO and wild type BALB/C mice (not shown).
This was not unexpected given the low affinity of FcγRII for IgG3 25 ; in addition, Kupffer cells, which appear to play a major role in mRBC destruction (D.A.S. and S.L.S., unpublished data;
and Ref. [26] [27] [28] [29] ), either lack FcγRIIb 30 or have defective regulation of phagocytosis by FcγRIIb 29 .
To examine the role of terminal complement components in IgG-mediated mRBC clearance, we compared wild type FVB/NJ mice, which lack complement component C5 22 , with wild type C57BL/6 mice. Clearance of hGPA-Tg-mRBC in MAb 10F7-immunized FVB/NJ mice was markedly reduced compared with C5-replete C57BL/6 mice (Tables 2-3 ). This suggests that complement C5 plays a significant role, perhaps because C5a enhances activating
Fcγ receptor function 31 . In contrast, there was little difference between FVB/NJ and C57BL/6 mice in the clearance of incompatible mRBC by the IgG3 NaM10-2H12 MAb (Tables 2-3) .
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Complement mediated hemolysis in vitro of IgM-coated hGPA-Tg-mRBC
hGPA-Tg-mRBC are susceptible to complement-mediated hemolysis in vitro in the presence of guinea pig serum. Thus, hGPA-Tg-mRBC coated in vitro with either the IgM E4 anti-GPA MAb or the IgM J11d anti-CD24 MAb were hemolyzed following incubation in complementcontaining serum, as were wild type mRBC coated with J11d ( Table 4) . As negative controls, wild type mRBC incubated with the E4 MAb, and uncoated hGPA-Tg-mRBC, were not hemolyzed. Thus, the hGPA epitope density on hGPA-Tg-mRBC and the avidity of MAb E4
were sufficient to activate complement, up to and including formation of functional C5b-9 membrane attack complexes.
IgM mediated hemolysis in vivo of transfused incompatible hGPA-Tg-mRBC
Dose-response and time course studies demonstrated that passive immunization intravenously of wild type C57BL/6 mice with 100 µg of the IgM anti-hGPA E4 MAb caused dramatic and very rapid clearance of transfused incompatible hGPA-Tg-mRBC (Table 5) (Table 5) .
By 2h post-transfusion, abundant, soluble, red-brown pigment was seen in the urine of all MAb E4-immunized wild type C57BL/6 mice transfused with hGPA-Tg-mRBC ( Figure 5A ).
This pigment was not pelleted by centrifugation (not shown); thus, this color change was not due to gross hematuria. However, spectrophotometry confirmed that the pigment was free hemoglobin with a peak absorbance at 414 nm ( Figure 5B) ; thus, the rapid clearance of transfused hGPA-Tg-mRBC produced gross hemoglobinuria ( Figure 5 ; Table 5 ). In contrast, no only.
For
These results strongly suggest that the IgM E4 anti-hGPA MAb rapidly produced dramatic, intravascular, complement-mediated hemolysis of transfused incompatible hGPA-Tg-mRBC.
To confirm the role of the membrane attack complex, FVB/NJ mice were used, which are C5 deficient 22 . Interestingly, the survival of transfused hGPA-Tg-mRBC in MAb E4-immunized FVB/NJ mice was only slightly less than that observed in complement-replete wild type C57BL/6 mice (not shown). However, no hemoglobinuria was observed in FVB/NJ recipients.
Thus, although complement-mediated intravascular hemolysis was strikingly evident in C57BL/6 mice, the predominant clearance mechanism was probably CR3-mediated phagocytosis of IgM/C3b-coated mRBC. This will be evaluated further in future studies using C3 KO and/or CVF-treated, complement deficient mice. The specific role of CR3, as opposed to CRIg 33 , can also be evaluated using CR3 KO mice 34 and the M1/70 CR3-blocking MAb 35, 36 . Finally, the role of C5 can be explored further using congenic strains that only differ at this locus 32 .
DISCUSSION
The need for mouse models to study immune-mediated hemolysis
Various animal models were used to study immune-mediated RBC destruction and its sequelae 7, [37] [38] [39] [40] . However, these are not optimal for studying human HTRs due to their expense and the limited flexibility. Although mRBC blood group systems were described 8 , and although antibody-mediated clearance of transfused, incompatible mRBC occurs 9,10 , these polymorphisms
were not exploited to study HTRs. However, murine AIHA models, which clear mRBC following infusion of monoclonal mRBC-specific autoantibodies . Therefore, the current study describes novel mouse models of alloantibodymediated intravascular and extravascular hemolysis, potentially suitable for studying HTR pathogenesis.
The relevance of Tg hGPA for immune-mediated hemolysis
Using hGPA-Tg-mRBC to study antibody-induced mRBC clearance is highly relevant for the human situation. Thus, hGPA is the most abundant human RBC glycoprotein 48, 49 .
The hGPA-Tg mouse provides a genetically inheritable, murine "blood group system."
Thus, wild-type mRBC are "antigen-negative" and hGPA-Tg-mRBC are "antigen positive."
Wild-type mice can be actively immunized with hGPA 53 and many mouse MAbs are available [12] [13] [14] [15] 18, 19, 53, [60] [61] [62] [63] . This type of blood group polymorphism (i.e. the presence or absence of an entire only.
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IgG-mediated hemolysis in passively immunized mice transfused with hGPA-Tg-mRBC
This study provides useful insights into the pathogenesis of antibody-mediated hemolysis. For example, the kinetics of IgG1-and IgG3-mediated clearance of hGPA-Tg-mRBC ( Figure 4 ; 29, 30 . Indeed, when using IgG class-switch variants of a monoclonal mRBC-specific autoantibody to induce AIHA, the IgG1 variant was moderately pathogenic 27, 43 ; furthermore, this variant's pathogenicity resulted from its interaction with activating Fcγ receptors. Therefore, the efficacy 10F7 ( Finally, in mouse ITP 25 and AIHA models 26, 27 IgG3 antibodies are either non-pathogenic or slightly pathogenic, respectively. In addition, in the latter, only complement was involved for this mild effect. However, in our in vivo studies NaM10-2H12 led to rapid and pronounced clearance of incompatible mRBC involving both complement and Fcγ receptors. These results are similar to those found with an IgG3 monoclonal anti-mRBC autoantibody 72 , although the roles of complement and Fcγ receptors were not assessed. Thus, the mechanisms of mRBC clearance by IgG3 Mabs may depend on additional factors, such as antigen specificity and antigen affinity. Studies directly comparing these systems (e.g. infusing anti-hGPA Mabs into hGPA-Tg mice as an AIHA model, and constructing Tg mice expressing hGPA on platelets as an ITP model) would provide additional insights.
Thus, this new model has characteristics that will deepen and extend the mechanistic understanding of IgG-mediated RBC destruction beyond that provided by existing models.
IgM-mediated hemolysis in passively immunized mice transfused with hGPA-Tg-mRBC
The IgM E4 anti-hGPA MAb produced dramatic, intravascular, complement-mediated hemolysis of transfused hGPA-Tg-mRBC (Table 5 ; Figure 5 ). To our knowledge, this represents the first time that an IgM has been effectively used to cause intravascular hemolysis in mice. Although only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From previous studies used monoclonal IgM anti-RBC MAbs to induce AIHA, the anemia was due to intravascular agglutination 41 . In contrast, given the small quantities of incompatible mRBC transfused in the current study, their clearance could only be caused by complement-mediated hemolysis and/or phagocytosis. Furthermore, the rapid kinetics of this IgM-mediated clearance agrees well with that in human IgM-HTRs 64 . Interestingly, despite the presence of the CD59 complement regulatory protein on hGPA-Tg-mRBC, and despite the impression that mouse complement is "weak" 73 , E4 caused complement-mediated intravascular hemolysis. Thus, this model will prove useful in unraveling and clarifying the pathogenic mechanisms of IgM-HTRs.
IgM-mediated intravascular hemolysis could also be enhanced by constructing hGPA-Tg x CD59 KO mice 74 and using these mRBC for transfusion.
When IgM-opsonized RBC were previously transfused into guinea pigs 37, 75 , they were rapidly cleared by the liver, and then released back into the circulation within 24h. The mechanism involved complement activation and adherence of IgM/C3b-coated RBC to complement receptors (presumably CR3), but not phagocytosis. In contrast, passively infused IgM E4 MAb not only rapidly cleared hGPA-Tg-mRBC, but the cleared mRBC were also not released back into the circulation (Table 5 ). One explanation is that the CR3 integrins in our mice were already activated (even though the mice are maintained in a barrier facility and less than 0.5 µ g of endotoxin contaminated the infused E4 MAb). Alternatively, the newly described CRIg complement receptor 33 , which does not require prior activation, may be responsible.
Finally, unique aspects of the specificity and/or affinity of MAb E4 may be relevant.
These mouse studies provided a surprising result that may be relevant to the pathogenesis of human IgM-HTRs. Thus, complement-mediated intravascular hemolysis has long been thought to be primarily responsible for destroying transfused incompatible RBC, as well as for the associated morbidity and mortality of human IgM-HTRs. Indeed, the signs of human IgMHTRs, including hemoglobinemia and hemoglobiunuria, provide solid evidence of intravascular hemolysis. However, without studying IgM-HTRs in a controlled setting, it has not been possible to determine the extent to which intravascular hemolysis clears transfused, incompatible RBC.
For example, the dramatic hemoglobinuria in MAb E4-immunized C57BL/6 recipients transfused with hGPA-Tg-mRBC provides clear evidence of intravascular hemolysis ( Figure 5 ).
Coupled with its rapid kinetics, it initially seemed that most, if not all, of the incompatible mRBC were destroyed intravascularly. Thus, the results of MAb E4-mediated mRBC clearance only.
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This suggests that, in contrast to what is believed with human IgM-HTRs, although complement does cause intravascular hemolysis of transfused, IgM-coated RBC, the IgM-mediated clearance of the incompatible RBC may be predominantly due to complement-mediated extravascular hemolysis resulting from phagocytosis by hepatic Kupffer cells and/or splenic macrophages.
Studies evaluating complement receptors (e.g. CR3 KO mice), early components in the complement cascade (e.g. C3 KO mice), and macrophage phagocytosis (e.g. using liposomal chlodronate) will provide more insight.
Future directions
Future studies will evaluate the relevance of this mouse model for human HTRs. In the current study, small amounts of radiolabeled incompatible mRBC were transfused into anesthetized mice. Despite rapid clearance of transfused mRBC, recipients did not display the clinical sequelae seen in human HTRs. Therefore, future studies will transfuse large quantities of incompatible mRBC and will monitor various physiological parameters 76 . Wild type FVB/NJ mice were passively immunized intraperitoneally with 500 µg of the purified 10F7 anti-hGPA IgG1 MAb (A) or with 50 µg of the purified NaM10-2H12 anti-hGPA IgG3
MAb (B). Sixteen hours later they were transfused with 51Cr-labeled hGPA-Tg-mRBC, and then RBC survival was quantified at the indicated time points. The number of mice evaluated at each time point is indicated in parentheses; the mean + 1 SD is provided for each time point.
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